#techbio — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #techbio, aggregated by home.social.
-
Breaking news from me this morning: Recursion Pharmaceuticals' Chris Gibson, who promised 100 drugs in 10 years in the early days of the tech-powered company, is stepping down as CEO.
https://www.statnews.com/2025/11/05/recursion-ceo-chris-gibson-out-najat-khan-new-head/#health #healthcare #medicine #biotech #techbio #pharma #ai #drugdiscovery
-
Breaking news from me this morning: Recursion Pharmaceuticals' Chris Gibson, who promised 100 drugs in 10 years in the early days of the tech-powered company, is stepping down as CEO.
https://www.statnews.com/2025/11/05/recursion-ceo-chris-gibson-out-najat-khan-new-head/#health #healthcare #medicine #biotech #techbio #pharma #ai #drugdiscovery
-
Breaking news from me this morning: Recursion Pharmaceuticals' Chris Gibson, who promised 100 drugs in 10 years in the early days of the tech-powered company, is stepping down as CEO.
https://www.statnews.com/2025/11/05/recursion-ceo-chris-gibson-out-najat-khan-new-head/#health #healthcare #medicine #biotech #techbio #pharma #ai #drugdiscovery
-
Breaking news from me this morning: Recursion Pharmaceuticals' Chris Gibson, who promised 100 drugs in 10 years in the early days of the tech-powered company, is stepping down as CEO.
https://www.statnews.com/2025/11/05/recursion-ceo-chris-gibson-out-najat-khan-new-head/#health #healthcare #medicine #biotech #techbio #pharma #ai #drugdiscovery
-
Breaking news from me this morning: Recursion Pharmaceuticals' Chris Gibson, who promised 100 drugs in 10 years in the early days of the tech-powered company, is stepping down as CEO.
https://www.statnews.com/2025/11/05/recursion-ceo-chris-gibson-out-najat-khan-new-head/#health #healthcare #medicine #biotech #techbio #pharma #ai #drugdiscovery
-
At Spring Science, we're using specialized AI to revolutionize drug discovery—accelerating the development of life-changing treatments by compressing years of progress into a fraction of the time.
Our AI platform analyzes vast biological data, uncovering insights that could take traditional methods decades to find. The future of medicine is here, driven by AI. Stay tuned! #AI #DrugDiscovery #TechBio
-
Exciting new collaboration that brings together clinical expertise in prostate cancer (second leading cause of cancer death for men) with the latest advances in instruments and AI technologies for atomic resolution of molecular structure. From our portfolio company Peptone based in Switzerland and the UK.
-
Exciting new collaboration that brings together clinical expertise in prostate cancer (second leading cause of cancer death for men) with the latest advances in instruments and AI technologies for atomic resolution of molecular structure. From our portfolio company Peptone based in Switzerland and the UK.
-
Exciting new collaboration that brings together clinical expertise in prostate cancer (second leading cause of cancer death for men) with the latest advances in instruments and AI technologies for atomic resolution of molecular structure. From our portfolio company Peptone based in Switzerland and the UK.
-
Exciting new collaboration that brings together clinical expertise in prostate cancer (second leading cause of cancer death for men) with the latest advances in instruments and AI technologies for atomic resolution of molecular structure. From our portfolio company Peptone based in Switzerland and the UK.
-
Exciting new collaboration that brings together clinical expertise in prostate cancer (second leading cause of cancer death for men) with the latest advances in instruments and AI technologies for atomic resolution of molecular structure. From our portfolio company Peptone based in Switzerland and the UK.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
The power comes from the ability to specify a one dimensional representation, the primary sequence, that will self-assemble into 3 dimensional structures. And the relatively simpler rules that govern this, due to the smaller diversity of charges and shapes of nucleotides (versus the larger diversity of amino acid residues) means it is more feasible to develop engineering rules for 3D designs.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
The power comes from the ability to specify a one dimensional representation, the primary sequence, that will self-assemble into 3 dimensional structures. And the relatively simpler rules that govern this, due to the smaller diversity of charges and shapes of nucleotides (versus the larger diversity of amino acid residues) means it is more feasible to develop engineering rules for 3D designs.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
The power comes from the ability to specify a one dimensional representation, the primary sequence, that will self-assemble into 3 dimensional structures. And the relatively simpler rules that govern this, due to the smaller diversity of charges and shapes of nucleotides (versus the larger diversity of amino acid residues) means it is more feasible to develop engineering rules for 3D designs.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
The power comes from the ability to specify a one dimensional representation, the primary sequence, that will self-assemble into 3 dimensional structures. And the relatively simpler rules that govern this, due to the smaller diversity of charges and shapes of nucleotides (versus the larger diversity of amino acid residues) means it is more feasible to develop engineering rules for 3D designs.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
The power comes from the ability to specify a one dimensional representation, the primary sequence, that will self-assemble into 3 dimensional structures. And the relatively simpler rules that govern this, due to the smaller diversity of charges and shapes of nucleotides (versus the larger diversity of amino acid residues) means it is more feasible to develop engineering rules for 3D designs.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
DNA sequencing is the “Moore’s Law” for biotech: transcriptomics, proteomics, spatial genomics, etc. leverage cheap/powerful sequencing to advance exponentially.
And now, the "inverse" of DNA sequencing is rising: DNA molecular engineering that use nucleic acids as programmable lego blocks for smart materials, such as DNA origami, strand-displacement, aptamers & molecular switches, etc.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
DNA sequencing is the “Moore’s Law” for biotech: transcriptomics, proteomics, spatial genomics, etc. leverage cheap/powerful sequencing to advance exponentially.
And now, the "inverse" of DNA sequencing is rising: DNA molecular engineering that use nucleic acids as programmable lego blocks for smart materials, such as DNA origami, strand-displacement, aptamers & molecular switches, etc.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
DNA sequencing is the “Moore’s Law” for biotech: transcriptomics, proteomics, spatial genomics, etc. leverage cheap/powerful sequencing to advance exponentially.
And now, the "inverse" of DNA sequencing is rising: DNA molecular engineering that use nucleic acids as programmable lego blocks for smart materials, such as DNA origami, strand-displacement, aptamers & molecular switches, etc.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
DNA sequencing is the “Moore’s Law” for biotech: transcriptomics, proteomics, spatial genomics, etc. leverage cheap/powerful sequencing to advance exponentially.
And now, the "inverse" of DNA sequencing is rising: DNA molecular engineering that use nucleic acids as programmable lego blocks for smart materials, such as DNA origami, strand-displacement, aptamers & molecular switches, etc.
-
CW: Are we entering a new age of nanotechnology based on nucleic acids?
DNA sequencing is the “Moore’s Law” for biotech: transcriptomics, proteomics, spatial genomics, etc. leverage cheap/powerful sequencing to advance exponentially.
And now, the "inverse" of DNA sequencing is rising: DNA molecular engineering that use nucleic acids as programmable lego blocks for smart materials, such as DNA origami, strand-displacement, aptamers & molecular switches, etc.
-
#Introduction Part 2:
My lab invented the open-source software CellProfiler and the imaging assay Cell Painting and we now focus on using our machine learning and deep learning skills for image-based profiling, to accelerate drug discovery and functional genomics. Our research led to the founding of Recursion, a clinical-stage techbio powered largely by the information in cell images.#CellProfiler #DrugDiscovery #TechBio #RXRX #MachineLearning #DeepLearning
-
#Introduction Part 2:
My lab invented the open-source software CellProfiler and the imaging assay Cell Painting and we now focus on using our machine learning and deep learning skills for image-based profiling, to accelerate drug discovery and functional genomics. Our research led to the founding of Recursion, a clinical-stage techbio powered largely by the information in cell images.#CellProfiler #DrugDiscovery #TechBio #RXRX #MachineLearning #DeepLearning
-
#Introduction Part 2:
My lab invented the open-source software CellProfiler and the imaging assay Cell Painting and we now focus on using our machine learning and deep learning skills for image-based profiling, to accelerate drug discovery and functional genomics. Our research led to the founding of Recursion, a clinical-stage techbio powered largely by the information in cell images.#CellProfiler #DrugDiscovery #TechBio #RXRX #MachineLearning #DeepLearning
-
#Introduction Part 2:
My lab invented the open-source software CellProfiler and the imaging assay Cell Painting and we now focus on using our machine learning and deep learning skills for image-based profiling, to accelerate drug discovery and functional genomics. Our research led to the founding of Recursion, a clinical-stage techbio powered largely by the information in cell images.#CellProfiler #DrugDiscovery #TechBio #RXRX #MachineLearning #DeepLearning
-
#Introduction Part 2:
My lab invented the open-source software CellProfiler and the imaging assay Cell Painting and we now focus on using our machine learning and deep learning skills for image-based profiling, to accelerate drug discovery and functional genomics. Our research led to the founding of Recursion, a clinical-stage techbio powered largely by the information in cell images.#CellProfiler #DrugDiscovery #TechBio #RXRX #MachineLearning #DeepLearning
-
Here’s my #introduction:
I'm a VC investing in DeepTech and TechBio, based in Silicon Valley. I'm focused on technologies related to data/compute/AI, such as semiconductors, machine learning, quantum computing, biology+data, and blockchain infrastructure (e.g., zero knowledge proof). My spare time is mostly taken up by a "random walk" exploration to learn math and physics.
#DeepTech #TechBio #VC
#Math #Physics #Biology #nanotechnology
#generativeAI #AI #zeroKnowledgeProof
#privacy -
Here’s my #introduction:
I'm a VC investing in DeepTech and TechBio, based in Silicon Valley. I'm focused on technologies related to data/compute/AI, such as semiconductors, machine learning, quantum computing, biology+data, and blockchain infrastructure (e.g., zero knowledge proof). My spare time is mostly taken up by a "random walk" exploration to learn math and physics.
#DeepTech #TechBio #VC
#Math #Physics #Biology #nanotechnology
#generativeAI #AI #zeroKnowledgeProof
#privacy -
Here’s my #introduction:
I'm a VC investing in DeepTech and TechBio, based in Silicon Valley. I'm focused on technologies related to data/compute/AI, such as semiconductors, machine learning, quantum computing, biology+data, and blockchain infrastructure (e.g., zero knowledge proof). My spare time is mostly taken up by a "random walk" exploration to learn math and physics.
#DeepTech #TechBio #VC
#Math #Physics #Biology #nanotechnology
#generativeAI #AI #zeroKnowledgeProof
#privacy -
Here’s my #introduction:
I'm a VC investing in DeepTech and TechBio, based in Silicon Valley. I'm focused on technologies related to data/compute/AI, such as semiconductors, machine learning, quantum computing, biology+data, and blockchain infrastructure (e.g., zero knowledge proof). My spare time is mostly taken up by a "random walk" exploration to learn math and physics.
#DeepTech #TechBio #VC
#Math #Physics #Biology #nanotechnology
#generativeAI #AI #zeroKnowledgeProof
#privacy -
Here’s my #introduction:
I'm a VC investing in DeepTech and TechBio, based in Silicon Valley. I'm focused on technologies related to data/compute/AI, such as semiconductors, machine learning, quantum computing, biology+data, and blockchain infrastructure (e.g., zero knowledge proof). My spare time is mostly taken up by a "random walk" exploration to learn math and physics.
#DeepTech #TechBio #VC
#Math #Physics #Biology #nanotechnology
#generativeAI #AI #zeroKnowledgeProof
#privacy -
Looking to follow (and be followed!) #mlbio #bioml #biotech #bayes #bayesian #generativemodels #startup #startups #medicine #biology #representationlearning #techbio #immunology #neurips #icml #iclr #cambridge #nyc
-
Looking to follow (and be followed!) #mlbio #bioml #biotech #bayes #bayesian #generativemodels #startup #startups #medicine #biology #representationlearning #techbio #immunology #neurips #icml #iclr #cambridge #nyc
-
Looking to follow (and be followed!) #mlbio #bioml #biotech #bayes #bayesian #generativemodels #startup #startups #medicine #biology #representationlearning #techbio #immunology #neurips #icml #iclr #cambridge #nyc
-
Looking to follow (and be followed!) #mlbio #bioml #biotech #bayes #bayesian #generativemodels #startup #startups #medicine #biology #representationlearning #techbio #immunology #neurips #icml #iclr #cambridge #nyc
-
Looking to follow (and be followed!) #mlbio #bioml #biotech #bayes #bayesian #generativemodels #startup #startups #medicine #biology #representationlearning #techbio #immunology #neurips #icml #iclr #cambridge #nyc
-
Just joined and here’s my #introduction:
I'm a venture investor in DeepTech and TechBio, based in Silicon Valley. I am focused on technologies that help to scale or to make use of the Data Stack, such as semiconductors, machine learning, quantum computing, digital health, and blockchain infrastructure (e.g., zero knowledge proof). In my ample spare time, I enjoy exercise, eating, messaging my son, and studying math and physics.
-
Just joined and here’s my #introduction:
I'm a venture investor in DeepTech and TechBio, based in Silicon Valley. I am focused on technologies that help to scale or to make use of the Data Stack, such as semiconductors, machine learning, quantum computing, digital health, and blockchain infrastructure (e.g., zero knowledge proof). In my ample spare time, I enjoy exercise, eating, messaging my son, and studying math and physics.